Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

argenx NV ADR

ARGX
Current price
596.20 USD +5.3 USD (+0.90%)
Last closed 550.00 USD
ISIN US04016X1019
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 33 314 447 360 USD
Yield for 12 month +66.35 %
1Y
3Y
5Y
10Y
15Y
ARGX
21.11.2021 - 28.11.2021

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. Address: Laarderhoogtweg 25, Amsterdam, Netherlands, 1101 EB

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

786.89 USD

P/E ratio

42.77

Dividend Yield

Current Year

+2 190 231 000 USD

Last Year

+1 226 316 000 USD

Current Quarter

+1 303 249 599 USD

Last Quarter

+573 236 000 USD

Current Year

+1 962 942 000 USD

Last Year

+1 108 481 000 USD

Current Quarter

+661 425 491 USD

Last Quarter

+514 164 000 USD

Key Figures ARGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -16 323 000 USD
Operating Margin TTM 13.41 %
Price to Earnings 42.77
Return On Assets TTM -0.21 %
PEG Ratio
Return On Equity TTM 17.36 %
Wall Street Target Price 786.89 USD
Revenue TTM 2 248 205 056 USD
Book Value 90.49 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 81.30 %
Dividend Yield
Gross Profit TTM 1 037 492 992 USD
Earnings per share 12.77 USD
Diluted Eps TTM 12.77 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin 37.05 %

Dividend Analytics ARGX

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History ARGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio
Last Split Date

Stock Valuation ARGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 42.77
Forward PE 80.65
Enterprise Value Revenue 13.36
Price Sales TTM 14.82
Enterprise Value EBITDA 278.27
Price Book MRQ 6.06

Financials ARGX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARGX

For 52 weeks

352.77 USD 678.21 USD
50 Day MA 613.80 USD
Shares Short Prior Month 2 232 259
200 Day MA 569.94 USD
Short Ratio 6.89
Shares Short 2 145 488
Short Percent 4.06 %